These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 17084172)
1. The case for secondary hormonal therapies in the chemotherapy age. Small EJ; Ryan CJ J Urol; 2006 Dec; 176(6 Pt 2):S66-71. PubMed ID: 17084172 [TBL] [Abstract][Full Text] [Related]
3. Novel secondary hormonal therapy in advanced prostate cancer: an update. Van Allen EM; Ryan CJ Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958 [TBL] [Abstract][Full Text] [Related]
4. Secondary hormonal manipulations in prostate cancer. Ryan CJ Hematol Oncol Clin North Am; 2006 Aug; 20(4):925-34. PubMed ID: 16861123 [TBL] [Abstract][Full Text] [Related]
5. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
6. Management of hormone refractory prostate cancer: current standards and future prospects. Oh WK; Kantoff PW J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323 [TBL] [Abstract][Full Text] [Related]
7. Secondary hormonal therapy. Smith DC Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134 [TBL] [Abstract][Full Text] [Related]
8. Secondary hormonal manipulations in prostate cancer. Ryan CJ; Small EJ Curr Oncol Rep; 2005 May; 7(3):228-33. PubMed ID: 15847715 [TBL] [Abstract][Full Text] [Related]
10. The case for systemic therapy alone for prostate cancer. Sweeney C J Urol; 2006 Dec; 176(6 Pt 2):S42-6. PubMed ID: 17084165 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms leading to the development of hormone-resistant prostate cancer. Kasper S; Cookson MS Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458 [TBL] [Abstract][Full Text] [Related]
12. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Sartor O; Gomella LG; Gagnier P; Melich K; Dann R Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". Ryan CJ; Eisenberger M J Clin Oncol; 2005 Nov; 23(32):8242-6. PubMed ID: 16278479 [TBL] [Abstract][Full Text] [Related]
14. Managing prostate cancer: the role of hormone therapy. Ramirez ML; Keane TE; Evans CP Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939 [TBL] [Abstract][Full Text] [Related]